A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF-07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06717425

Enrollment

263

Registered

2024-12-05

Start date

2024-12-09

Completion date

2026-01-12

Last updated

2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity

Brief summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants who take placebo (a lookalike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight and how well they tolerate the study medicine.

Interventions

DRUGPF-07976016

Taken once daily

DRUGPlacebo

Taken once daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Intervention model description

This is a randomized, double-blind (investigator and participant), sponsor-open, placebo-controlled study.

Eligibility

Sex/Gender

ALL

Age

18 Years to 74 Years

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * Male or non-pregnant, non-breastfeeding female, 18 to 74 years of age at Visit 1 * Body Mass Index ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as \<5 kg change in the 12 weeks before Visit 1 * Eligible and willing to receive required background medicine * Willing and able to comply with all study procedures Key

Exclusion criteria

* Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes. * Use of any prohibited prior or concomitant medication(s) * Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests at Visit 1.

Design outcomes

Primary

Measure	Time frame
Percent change from baseline in body weight	Baseline to Week 16

Secondary

Measure	Time frame
Number of participants with treatment emergent adverse events	From first dose (Day 1) up to 28-35 days after final dose, a total of approximately 21 weeks

Countries

Canada, Poland, United States

Contacts

STUDY_DIRECTORPfizer CT.gov Call Center

Pfizer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026